APA (7th ed.) Citation

BP, N., L, K., LD, M., JJ, A., B, C., F, R., . . . PW, N. (2025). Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: A multicentre, observer-blind, randomised, phase 3 study. The Lancet. Global health, 13(12), e2122. https://doi.org/10.1016/S2214-109X(25)00330-4

Chicago Style (17th ed.) Citation

BP, Ndiaye, et al. "Safety and Non-inferiority of Multidose and Single-dose Vial Formulations of EuTCV Vi-CRM197 Versus Typbar TCV in Healthy Participants in Kenya and Senegal: A Multicentre, Observer-blind, Randomised, Phase 3 Study." The Lancet. Global Health 13, no. 12 (2025): e2122. https://doi.org/10.1016/S2214-109X(25)00330-4.

MLA (9th ed.) Citation

BP, Ndiaye, et al. "Safety and Non-inferiority of Multidose and Single-dose Vial Formulations of EuTCV Vi-CRM197 Versus Typbar TCV in Healthy Participants in Kenya and Senegal: A Multicentre, Observer-blind, Randomised, Phase 3 Study." The Lancet. Global Health, vol. 13, no. 12, 2025, p. e2122, https://doi.org/10.1016/S2214-109X(25)00330-4.